Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 43 (6), 328-331

Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia

Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia

Stepan Uhlyar et al. P T.

Abstract

Valbenazine (Ingrezza): the first FDA-approved treatment for tardive dyskinesia.

Conflict of interest statement

Disclosures: Dr. Rey serves on the Advisory Board and Speakers’ Bureau at Neurocrine Biosciences. Dr. Uhlyar reports no commercial or financial interests in regard to this article.

Figures

Figure 1
Figure 1
Chemical Structure Of Valbenazine

Similar articles

  • Valbenazine for the Treatment of Tardive Dyskinesia
    N Barquero. Drugs Today (Barc) 52 (12), 665-672. PMID 28276538. - Review
    Valbenazine (NBI-98854, Ingrezza) is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor that modulates dopamine release during nerve communication. Th …
  • Valbenazine for Tardive Dyskinesia
    O Freudenreich et al. Clin Schizophr Relat Psychoses 11 (2), 113-119. PMID 28742396. - Review
    Tardive dyskinesia (TD) remains a clinical concern for any patient who receives an antipsychotic. While the overall risk of developing TD is lower with newer antipsychoti …
  • Valbenazine in the Treatment of Tardive Dyskinesia
    N Witek et al. Neurodegener Dis Manag 9 (2), 73-81. PMID 30724115.
    Tardive dyskinesia (TD) is a bothersome and - at times, disabling - movement disorder associated with exposure to dopamine receptor antagonist medications. On 11 April 20 …
  • Valbenazine as the First and Only Approved Treatment for Adults With Tardive Dyskinesia
    H Sarva et al. Expert Rev Clin Pharmacol 11 (3), 209-217. PMID 29338466. - Review
    Valbenazine is a selective VMAT2 inhibitor that the FDA approved in April 2017 for the specific treatment of tardive dyskinesia (TD), a movement disorder commonly caused …
  • Valbenazine Granted Breakthrough Drug Status for Treating Tardive Dyskinesia
    T Müller. Expert Opin Investig Drugs 24 (6), 737-42. PMID 25809133.
    The chronic use and high dosing of typical neuroleptics or centrally acting dopamine receptor blocking antiemetics predispose patients to the onset of tardive syndromes. …
See all similar articles

Cited by 1 PubMed Central articles

  • Antipsychotics for Patients With Pain
    SW Shin et al. Korean J Pain 32 (1), 3-11. PMID 30671198. - Review
    Going back to basics prior to mentioning the use of antipsychotics in patients with pain, the International Association for the Study of Pain (IASP) definition of pain ca …

LinkOut - more resources

Feedback